alogliptin vs januvia | Alogliptin vs Januvia Comparison

Keyword	CPC	PCC	Volume	Score	Length of keyword
alogliptin vs januvia	0.48	0.7	4465	89	21
alogliptin	0.95	0.5	2147	35	10
vs	2	0.9	8132	52	2
januvia	1.9	0.9	4218	72	7

Keyword	CPC	PCC	Volume	Score
alogliptin vs januvia	0.75	0.6	2417	71
alogliptin vs januvia dosing	0.33	0.4	6769	68
alogliptin vs januvia conversion	0.04	0.9	5262	12
alogliptin benzoate vs januvia	0.86	0.8	7124	47
alogliptin 25mg vs januvia 100mg	0.56	0.3	2003	29
alogliptin 25mg to januvia	1.24	0.3	5092	23
alogliptin compared to januvia	1.52	0.3	1569	56
alogliptin equivalent to januvia	0.37	0.1	5238	45
januvia to alogliptin conversion	0.18	0.4	1879	23
difference between januvia and alogliptin	0.01	0.6	4276	61
is alogliptin the same as januvia	1.28	0.6	1967	13
dosage and administration of januvia	1.7	0.2	6240	26
what are the doses of januvia	0.61	0.7	7801	27
januvia to linagliptin conversion	1.01	0.7	8349	17
normal dose of januvia	0.66	0.8	7813	43
januvia dosage for adults	1.37	0.4	2085	75
what is the lowest dose of januvia	0.27	0.1	4920	92
starting dose for januvia	0.33	0.1	8755	84
max dose for januvia	1.49	0.8	3756	76
januvia doses 50 mg	1.14	0.3	2649	34

Search Results related to alogliptin vs januvia on Search Engine

Alogliptin vs Januvia Comparison - Drugs.com
drugs.com

https://www.drugs.com/compare/alogliptin-vs-januvia

WebCompare Alogliptin vs Januvia head-to-head with other drugs for uses, ratings, cost, side effects and interactions.

DA: 79 PA: 92 MOZ Rank: 81

Alogliptin vs Januvia | Power
withpower.com

https://www.withpower.com/guides/alogliptin-vs-januvia-fbb4

WebUnlike Alogliptin, Januvia has been around for a longer period of time and has more robust clinical trial data supporting its use in managing blood sugar levels in type 2 diabetics. This makes it a preferred choice among many physicians when choosing between these two medications. How effective are both Alogliptin and Januvia?

DA: 61 PA: 73 MOZ Rank: 4

What Are My Options for Type 2 Diabetes Medications? | ADA
diabetes.org

https://diabetes.org/health-wellness/medication/oral-other-injectable-diabetes-medications

WebAlogliptin (Nesina) Linagliptin (Tradjenta) Saxagliptin (Onglyza) Sitagliptin (Januvia) GLP-1 and Dual GLP-1/GIP Receptor Agonists. As noted in the description for DPP-4 inhibitors, GLP-1 and GIP are natural hormones in the body that help maintain glucose levels.

DA: 77 PA: 84 MOZ Rank: 23

DPP-IV Inhibitors | Johns Hopkins Diabetes Guide
hopkinsguides.com

https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547042/all/DPP_IV_Inhibitors

WebDec 3, 2018 · Alogliptin; GFR ≥ 60 mL/min, no dosage adjustment needed; GFR ≥30 to < 60 mL/minute: 12.5 mg once daily; GFR ≥15 to < 30 mL/minute: 6.25 mg once daily; ESRD (GFR < 15 mL/minute or requiring hemodialysis): 6.25 mg once daily; administered without regard to timing of hemodialysis; HEPATIC HEPATIC

DA: 25 PA: 88 MOZ Rank: 27

Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment ... - UpToDate
uptodate.com

https://www.uptodate.com/contents/dipeptidyl-peptidase-4-dpp-4-inhibitors-for-the-treatment-of-type-2-diabetes-mellitus

WebApr 27, 2023 · This topic will review the mechanism of action and therapeutic utility of DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. GLP-1 receptor agonists are discussed separately. General discussions of the initial management of blood glucose and the management of persistent hyperglycemia in adults with type 2 diabetes are also ...

DA: 52 PA: 43 MOZ Rank: 10

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145895/

WebApr 3, 2020 · Both DPP-4 inhibitors and GLP-1 RAs have demonstrated safety in robust cardiovascular outcome trials, while several GLP-1 RAs have been shown to significantly reduce the risk of major adverse cardiovascular events in persons with T2DM with pre-existing cardiovascular disease (CVD).

DA: 71 PA: 72 MOZ Rank: 100

Evaluating Type 2 Medications, Part 4: - Taking Control Of Your Diabetes®
tcoyd.org

https://tcoyd.org/2019/01/evaluating-type-2-medications-part-4-dpp-4-inhibitors-or-incretin-enhancers/

WebJan 18, 2019 · Evaluating Type 2 Medications, Part 4: DPP-4 Inhibitors or Incretin Enhancers. Januvia (sitagliptin), Onglyza (saxagliptin), Tradjenta (linagliptin), and Nesina (alogliptin) are members of a class of oral medications for type 2 diabetes called the DPP-4 inhibitors or incretin enhancers.

DA: 83 PA: 51 MOZ Rank: 10

Management of Blood Glucose with Noninsulin Therapies in Type …
aafp.org

https://www.aafp.org/pubs/afp/issues/2015/0701/p27.html

WebJul 1, 2015 · Alogliptin (Nesina) 25 mg daily: $340: Linagliptin (Tradjenta) 5 mg daily: $400: Saxagliptin (Onglyza) 2.5 to 5 mg daily: $350: Sitagliptin (Januvia) 50 to 100 mg daily: $360: Glucagon-like...

DA: 18 PA: 3 MOZ Rank: 11

Januvia: Side Effects, Dosage, Uses, Cost, and More - Healthline
healthline.com

https://www.healthline.com/health/drugs/januvia

WebAug 11, 2022 · Contents. Side effects. Dosage. Uses. FAQs. Cost. How to take. Januvia vs. Tradjenta. Januvia vs. metformin. What to consider. Overdose. Ask your doctor. Q&A. Drug Images. What is...

DA: 62 PA: 17 MOZ Rank: 18

Alogliptin (Nesina) for Adults With Type-2 Diabetes - PMC
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005122/

WebSitagliptin (Januvia, Merck) was approved in October 2006; saxagliptin (Onglyza, Bristol-Myers Squibb) was approved in July 2009; and linagliptin (Tradjenta, Boehringer Ingelheim) was approved in May 2011. The newest DPP-4 inhibitor, alogliptin, was …

DA: 34 PA: 99 MOZ Rank: 74